Published • loading... • Updated
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summary by BizToc
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
stock rocketed Thursday, and pushed Crescent Biopharma (CBIO) to a four-month high, after its experimental cancer drug outperformed Merck's (MRK) blockbuster, Keytruda. Patients with metastatic non-small cell lung cancer lived for longer before dying of any cause — a measure known as overall…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
